Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Executive Summary

As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.


Related Content

What's Next On Gilead's Shopping List
Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
Stealthy NGM And Bristol Emerge As Serious NASH Competitors
Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal
Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?
Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk
Gilead Plays Up Its Strength As Market Awaits Business Development Moves
Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH
The NASH Pipeline: Replete With Targets And New Compounds
Intercept quiet on NASH safety data disclosure concerns


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts